Definitive Clinical Oncology, Cellular Pathology & Genomic Biomarkers.
Homologous recombination deficiency (**HRD**) represents an impaired capacity to repair DNA double-strand breaks via error-free homologous recombination, sensitizing neoplastic cells to poly (ADP-ribose) polymerase...
ROS1 proto-oncogene rearrangements drive approximately 1 to 2 percent of advanced pulmonary adenocarcinomas, representing a distinct molecular subset characterized by younger patient age and...
Anaplastic lymphoma kinase (**ALK**) gene rearrangements drive approximately 3 to 7 percent of non-small cell lung carcinomas, frequently occurring in younger patients with minimal...
Circulating tumor DNA liquid biopsy provides high-sensitivity detection of minimal residual disease by analyzing cell-free tumor-derived nucleic acid fragments in peripheral blood. This methodology...
Programmed death-ligand 1 (PD-L1) expression quantified via tumor proportion score (TPS) serves as the primary companion diagnostic biomarker for immune checkpoint inhibitor therapy. High...
The KRAS G12C missense mutation represents a major oncogenic driver in non-small cell lung cancer, driven by a glycine-to-cysteine substitution at codon 12. Sotorasib...
HER2/neu amplification drives aggressive tumorigenesis via ERBB2 gene overexpression, warranting precise diagnostic evaluation and antibody-drug conjugate therapy. Trastuzumab deruxtecan delivers a potent topoisomerase I...
TP53 loss-of-function mutations represent the most frequent genomic alteration in human oncology, driving unrestrained genomic instability and tumorigenesis. Inactivation of the 17p13.1 locus impairs...
Deficient DNA mismatch repair (dMMR) and high microsatellite instability (MSI-H) constitute a molecular phenotype characterized by hypermutation and neoantigen generation. This validated pan-tumor biomarker...
Cyclin D1 overexpression and CDK4/6 gene amplification drive uncontrolled G1 to S phase cell cycle progression in hormone receptor-positive malignancies. Pharmacological inhibition using selective...
Estrogen receptor 1 (**ESR1**) ligand-binding domain mutations drive acquired endocrine resistance in metastatic estrogen receptor-positive breast carcinoma. These activating missense alterations occur predominantly following...
Fibroblast growth factor receptor 2 and 3 (FGFR2/3) genetic alterations drive oncogenesis in intrahepatic cholangiocarcinoma and advanced urothelial carcinoma. Selective tyrosine kinase inhibitors have...
Oncogenic fusions involving the **NTRK1**, **NTRK2**, and **NTRK3** genes drive constitutive activation of neurotrophin receptor tyrosine kinases across diverse adult and pediatric malignancies. Precision...
Rearranged during transfection (**RET**) gene fusions represent oncogenic drivers in approximately 1% to 2% of non-small cell lung carcinomas (**NSCLC**). The **KIF5B-RET** chimera is...
**MET exon 14 skipping mutations** occur in approximately 3% to 4% of lung adenocarcinomas and lead to impaired receptor degradation and aberrant downstream oncogenic...
Isocitrate dehydrogenase 1 (**IDH1**) and 2 (**IDH2**) neomorphic mutations catalyze the reduction of alpha-ketoglutarate to the oncometabolite D-2-hydroxyglutarate, driving hypermethylation and tumorigenesis in glioma...
Mutational activation of the **PIK3CA** gene occurs in approximately 40% of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast carcinomas. These...
KRAS G12D and G12V missense mutations represent the predominant oncogenic drivers in pancreatic ductal adenocarcinoma and lung adenocarcinoma, characterized by constitutive GTPase enzymatic inactivation...
Activating **BRAF V600E** and **V600K** mutations drive constitutional kinase activation within the **RAS-RAF-MEK-ERK** signaling cascade across malignant melanoma and colorectal carcinomas. Precision combinatorial therapies...
Acquired resistance to third-generation epidermal growth factor receptor tyrosine kinase inhibitors frequently involves secondary mutations such as T790M and tertiary mutations like C797S. These...